15 September 2011
Today, URCH Publishing a business information provider, launches a new report on the healthcare market in Latin America. Healthcare & Pharmaceuticals in Latin America - A guide to the markets and regulations provides an excellent overview of the healthcare and pharmaceutical market in 19 Latin American countries.
The 40,000 word report will provide the reader with an excellent review of the healthcare systems, politics, regulatory framework, major companies and key issues affecting this sector in the Latin American region.
The report provides information on key pharmaceutical issues such as market size, intellectual property, access to essential medicines, compulsory licensing and clinical trials. The 90 page report will be of particular interest to multinational companies considering expanding their operations in the region.
Edwin Bailey, managing director of URCH Publishing, commenting on the publication of the report said: “Although Latin America offers substantial business opportunities for companies, it is a volatile region in economic terms. There is considerable risk involved in investing in the region and companies need to be fully aware of past economic crises and their causes before becoming involved”.
Key features of this study include; an overview of healthcare systems in 19 Latin American countries, a review of the pharmaceutical market and major companies operating in each country, a guide to the relevant regulatory structure, with comment on intellectual property issues, and an evaluation of the role of the generics in the domestic market.
The report will help executives by ensuring that they understand the distinct characteristics of the Latin American pharmaceutical market and plan market strategy for successful entry and operation in the region. Additionally the reader will gain insight into some issues particular to the Latin American region, such as how some governments are planning to implement universal healthcare coverage and how generics are likely to be promoted as ‘essential medicines’.